Scientific Research on Ketones, Coconut Oil, and Brain Health
Explore published scientific research on ketones, coconut oil, medium-chain triglycerides (MCTs), and ketogenic diets. This collection of ketones and Alzheimer’s research includes clinical studies and scientific publications on Alzheimer’s disease, Parkinson’s disease, brain energy metabolism, and other neurological disorders.
The collection includes human clinical studies, scientific reviews, laboratory research, and foundational studies on brain energy metabolism. Research findings vary, and experimental results do not necessarily establish clinical benefits.
Compiled and maintained by Mary T. Newport, MD, physician, author of four books on ketones and brain health, and researcher exploring the potential of ketogenic therapies for Alzheimer’s disease and other neurological disorders.
Browse Research by Topic
Featured Research
Selected publications and scientific reviews exploring the potential roles of ketones, coconut oil, MCT oil, and ketogenic interventions in brain health, neurological disorders, and lipid metabolism.
Beyond Cognition: A Broader Range of Reported Improvements
In my published analysis of 288 caregiver and individual reports involving people with Alzheimer’s disease and other memory impairments who consumed coconut oil and/or MCT oil, 89.2% reported some type of improvement. Memory or cognition improvements were reported in 65.3%, while others described changes in speech, conversation, social interaction, behavior, mood, self-care, physical symptoms, sleep, and other areas of daily life. Many individuals reported improvements in more than one category.
These anecdotal observations cannot establish treatment efficacy, but they highlight the importance of investigating outcomes beyond memory and cognitive testing. Improvements in communication, mood, mobility, independence, and quality of life may also be meaningful to people with neurological disorders and their caregivers.
Future Research Directions
An important direction for future clinical research is to compare coconut oil, C8/C10 MCT oil, ketone supplements, ketogenic diets, and combinations of these interventions. Differences in fatty acid composition, ketone availability, and other metabolic effects may influence clinical responses and tolerability.
Future randomized controlled trials should evaluate a broad range of outcomes beyond memory and cognitive testing, including activities of daily living, mood and behavior, quality of life, physical function, mobility, and muscle strength. These measures may identify meaningful changes in independence, communication, emotional well-being, and the ability to perform everyday activities that are not adequately captured by conventional cognitive assessments.
Such studies could help determine which interventions offer benefits, which symptoms are most responsive, and whether different formulations provide distinct advantages for people with Alzheimer’s disease, Parkinson’s disease, and other neurological disorders.
Ketogenic Strategies for Alzheimer’s Disease and Other Memory Impairments: History, Rationale, and 288 Caregiver Case Reports
Mary T. Newport, MD
Medical Research Archives, April 30, 2024
This article reviews the history and scientific rationale for ketogenic strategies in Alzheimer’s disease and other memory impairments, including observations from 288 caregiver case reports.
Lower Brain 18F-Fluorodeoxyglucose Uptake But Normal 11C-Acetoacetate Metabolism in Mild Alzheimer’s Disease Dementia
Castellano CA, Nugent S, Paquet N, and colleagues
Journal of Alzheimer’s Disease, 2015; 43(4):1343-1353
In this PET imaging study, 10 people with mild Alzheimer’s disease were compared with 29 cognitively normal older adults to evaluate brain glucose and ketone metabolism. Global gray matter glucose metabolism was 13% lower in the Alzheimer’s group, with particularly affected regions including the parietal cortex, posterior cingulate, and thalamus. In contrast, acetoacetate (a ketone body) uptake and metabolism did not differ significantly between groups. These findings provide important evidence that the Alzheimer’s brain retains its capacity to metabolize ketones despite impaired glucose metabolism, supporting further investigation of ketogenic interventions as a potential means of improving brain energy availability.
A New Way to Produce Hyperketonemia: Use of Ketone Ester in a Case of Alzheimer’s Disease
Newport MT, VanItallie TB, Kashiwaya Y, King MT, Veech RL
Alzheimer’s & Dementia, 2015; 11(1):99-103
This case report describes 20 months of oral ketone monoester supplementation in a man with early-onset Alzheimer’s disease and a pretreatment MMSE score of 12. During treatment, improvements were observed in mood, cognition, conversation, self-care, and daily activities. Cognitive and behavioral responses appeared to vary with blood beta-hydroxybutyrate concentrations, with more noticeable improvements at higher levels. The ketone ester was well tolerated throughout treatment. Although findings from one patient cannot establish treatment efficacy, this report provided early evidence of the feasibility of sustained ketone ester administration in Alzheimer’s disease.
Impact of Coconut Oil and Its Bioactive Metabolites in Alzheimer’s Disease and Dementia: A Systematic Review and Meta-Analysis
Bafail D, Bafail A, Alshehri N, Alhalees NH, Bajarwan A
Diseases, 2024; 12:272
This systematic review and meta-analysis examined studies of coconut oil and its bioactive components in Alzheimer’s disease and dementia. The authors reported improvements in cognitive scores associated with coconut oil interventions, although further well-designed clinical trials are needed.
Analysis of 26 Studies of the Impact of Coconut Oil on Lipid Parameters: Beyond Total and LDL Cholesterol
Mary T. Newport, MD, and Fabian M. Dayrit, PhD
Nutrients, 2025; 17(3):514
This analysis examined 984 lipid-profile datasets from 26 studies of coconut oil consumption conducted over approximately 40 years. Overall, coconut oil was associated with increased HDL cholesterol and reduced triglycerides, while total and LDL cholesterol responses were variable. The authors also examined cholesterol ratios and the differences between coconut oil and other saturated fats.
The Lipid-Heart Hypothesis and the Keys Equation Defined the Dietary Guidelines but Ignored the Impact of Trans-Fat and High Linoleic Acid Consumption
Mary T. Newport, MD, and Fabian M. Dayrit, PhD
Nutrients, 2024; 16(10):1447
This review examines the historical development of the lipid-heart hypothesis and dietary recommendations to reduce saturated fat and cholesterol. The authors critically evaluate major dietary fat studies and discuss how industrial trans-fats and high linoleic acid consumption may have influenced the interpretation of research on cholesterol and cardiovascular disease.
Alzheimer’s Disease & Mild Cognitive Impairment
Human clinical studies investigating coconut oil, medium-chain triglycerides (MCTs), ketone supplements, and ketogenic diets in people with Alzheimer’s disease or mild cognitive impairment (MCI).
Potential of Coconut Oil and Medium Chain Triglycerides in the Prevention and Treatment of Alzheimer’s Disease
Chatterjee P, Fernando M, Fernando B, and colleagues
Mechanisms of Ageing and Development, 2020; 186:111209. Review.
This comprehensive review examines the potential roles of coconut oil and medium-chain triglycerides (MCTs) in Alzheimer’s disease. The authors discuss brain glucose hypometabolism and the ability of ketones to provide an alternative energy source. They also review evidence concerning cognitive function, amyloid-beta pathology, inflammation, oxidative stress, and the possible neuroprotective effects of coconut oil components, including polyphenols. Particular attention is given to the digestion and metabolism of medium-chain fatty acids, including lauric acid (C12), and important gaps in the evidence that require further clinical investigation.
A Combination of Ketones and NAD+ Precursor Preserves White Matter Integrity in Mild Cognitive Impairment
Roy M, Fortier M, St-Pierre V, and colleagues
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2026; 12(2):e70278. Published June 22, 2026.
In the six-month randomized, placebo-controlled BREAK-AD trial, 30 participants with mild cognitive impairment completed treatment with a combination of beta-hydroxybutyrate (BHB) salts and the NAD+ precursor nicotinamide riboside or placebo. Ketone uptake increased 2.4-fold in gray matter and 3.1–3.6-fold in white matter tracts. Myelin density declined in certain regions of the fornix in the placebo group but was preserved in the treatment group. Increased white matter ketone uptake and myelin measures were associated with improved processing speed. These preliminary findings suggest a potential role for ketogenic supplementation in maintaining white matter integrity.
Effect of Virgin Coconut Oil Supplementation on Cognition of Individuals with Mild-to-Moderate Alzheimer’s Disease in Sri Lanka (VCO-AD Study): A Randomized Placebo-Controlled Trial
Fernando MG, Silva R, Fernando WMADB, and colleagues
Journal of Alzheimer’s Disease, 2023; 96(3):1195-1206
In this randomized, double-blind trial, 120 people with mild-to-moderate Alzheimer’s disease were assigned to receive either 30 mL of virgin coconut oil or canola oil daily for 24 weeks. There was no significant overall difference in cognitive outcomes between groups. However, improved MMSE scores were observed among APOE4 carriers receiving coconut oil compared with non-carriers. No significant differences in lipid profiles or HbA1c were found between treatment groups.
A Ketogenic Supplement Improves White Matter Energy Supply and Processing Speed in Mild Cognitive Impairment
Roy M, Fortier M, Rheault F, and colleagues
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2021; 7(1):e12217
This analysis of 33 participants from the BENEFIC trial examined white matter energy metabolism following six months of ketogenic MCT supplementation. Ketone uptake increased approximately 2.5- to 3.2-fold in nine white matter tracts. Greater white matter ketone uptake was associated with improvements in processing speed, particularly in the fornix. These findings suggest that ketones may help support white matter energy metabolism in people with mild cognitive impairment.
A Ketogenic Intervention Improves Dorsal Attention Network Functional and Structural Connectivity in Mild Cognitive Impairment
Roy M, Edde M, Fortier M, and colleagues
Neurobiology of Aging, 2022; 115:77-87
This analysis of 32 participants from the BENEFIC trial examined changes in brain network connectivity following six months of ketogenic MCT supplementation. The intervention increased functional connectivity within the dorsal attention network, which was associated with improvements in attention-related cognitive testing. Increased ketone uptake in this network was associated with stronger functional connectivity, and structural imaging showed increased fiber density. These findings suggest that improved brain energy availability from ketones may support neuronal connectivity and cognitive function.
Randomized Crossover Trial of a Modified Ketogenic Diet in Alzheimer’s Disease
Phillips MCL, Deprez LM, Mortimer GMN, and colleagues
Alzheimer’s Research & Therapy, 2021; 13:51
In this randomized crossover trial, 26 people with Alzheimer’s disease were assigned to follow a modified ketogenic diet or their usual diet with low-fat healthy-eating guidelines for 12 weeks each, separated by a 10-week washout period. Twenty-one participants completed the ketogenic diet, achieving an average blood beta-hydroxybutyrate level of 0.95 mmol/L. Compared with the usual diet, the ketogenic diet significantly improved activities of daily living and quality of life. Cognitive scores also increased modestly, but the difference was not statistically significant. The ketogenic diet included recipes using coconut oil and coconut milk.
| Read Full Article (PDF) → |
| Download The Ketogenic Way – Diet and Recipe Manual (PDF) → |
Use of Medium Chain Triglyceride (MCT) Oil in Subjects with Alzheimer’s Disease: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study, with an Open-Label Extension
Juby AG, Blackburn TE, Mager DR
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022; 8(1):e12259
This study enrolled 20 people with mild-to-moderate Alzheimer’s disease in a randomized, placebo-controlled crossover trial followed by an open-label extension. Participants received MCT oil at a target dose of 42 g daily or the maximum tolerated dose, averaging approximately 25 g daily. Eighty percent experienced stabilization or improvement in cognitive testing over the study period. Longer MCT exposure was associated with better cognitive outcomes. Gastrointestinal side effects were common but generally manageable with dose adjustments. These preliminary findings support further investigation of long-term MCT supplementation in Alzheimer’s disease.
Effects of a Medium-Chain Triglyceride-Based Ketogenic Formula on Cognitive Function in Patients with Mild-to-Moderate Alzheimer’s Disease
Ota M, Matsuo J, Ishida I, and colleagues
Neuroscience Letters, 2019; 690:232-236
This Japanese study enrolled 20 people with mild-to-moderate Alzheimer’s disease to evaluate an MCT-based ketogenic formula containing 20 g of MCTs per serving. A single dose significantly increased blood ketones but did not improve cognitive test scores compared with placebo. Participants then received the ketogenic formula daily for up to 12 weeks, with 16 completing the study. Compared with baseline, significant improvements were observed in immediate and delayed verbal memory at eight weeks and in immediate verbal memory and digit-symbol coding at 12 weeks. Because the longer intervention lacked a placebo control group, these findings are preliminary but support further investigation of sustained MCT supplementation in Alzheimer’s disease.
Study of the Ketogenic Agent AC-1202 in Mild to Moderate Alzheimer’s Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial
Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC
Nutrition & Metabolism, 2009; 6:31
This 90-day randomized, double-blind, placebo-controlled trial enrolled 152 people with mild-to-moderate Alzheimer’s disease to evaluate AC-1202, a ketogenic formulation containing caprylic triglyceride (C8). Blood beta-hydroxybutyrate levels increased significantly following supplementation. Compared with placebo, the treatment group showed a significant improvement in ADAS-Cog scores at 45 days, but not at 90 days in the overall study population. Participants who did not carry the APOE4 allele showed significant cognitive benefits at both 45 and 90 days. Gastrointestinal side effects were more frequent with AC-1202. This early clinical trial provided evidence supporting further investigation of ketone-based interventions in Alzheimer’s disease.
Pharmacogenetic Analysis of the Effects of Polymorphisms in APOE, IDE and IL1B on a Ketone Body Based Therapeutic on Cognition in Mild to Moderate Alzheimer’s Disease: A Randomized, Double-Blind, Placebo-Controlled Study
Henderson ST, Poirier J
BMC Medical Genetics, 2011; 12:137
This follow-up analysis of the 90-day AC-1202 clinical trial examined whether genetic variations in APOE, IDE, and IL1B influenced cognitive responses to ketogenic supplementation. The researchers found that APOE genotype was associated with treatment response, with the greatest cognitive benefits observed among participants who did not carry the APOE4 allele. The findings suggest that genetic differences may influence responses to ketone-based interventions in Alzheimer’s disease.
Retrospective Cohort Study of the Efficacy of Caprylic Triglyceride in Patients with Mild-to-Moderate Alzheimer’s Disease
Maynard SD, Gelblum J
Neuropsychiatric Disease and Treatment, 2013; 9:1619-1627
This retrospective study reviewed the medical records and caregiver assessments of 55 people with mild-to-moderate Alzheimer’s disease who received caprylic triglyceride (C8) for at least six months in addition to standard medications. Approximately 80% were rated by their physicians as stable or improved. Among 27 participants with available cognitive testing, average MMSE scores remained relatively stable over 15 months. Caregivers also reported stabilization or improvement in memory and activities of daily living in many patients. These observations are encouraging, although the retrospective design and absence of a control group limit conclusions about treatment effectiveness.
Retrospective Case Studies of the Efficacy of Caprylic Triglyceride in Mild-to-Moderate Alzheimer’s Disease
Maynard SD, Gelblum J
Neuropsychiatric Disease and Treatment, 2013; 9:1629-1635
This retrospective case series examined eight people with mild-to-moderate Alzheimer’s disease who received caprylic triglyceride (C8) for at least six months in addition to their usual medications. Changes in MMSE scores varied among patients, with some experiencing stabilization or modest improvement while others continued to decline. The average annual rate of cognitive decline was numerically lower after supplementation, although the difference was not statistically significant. These findings illustrate the variability in individual responses and support further controlled studies of ketogenic interventions in Alzheimer’s disease.
Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer’s Disease
Croteau E, Castellano CA, Richard MA, and colleagues
Journal of Alzheimer’s Disease, 2018; 64(2):551-561
This study used PET imaging to evaluate brain ketone and glucose metabolism in people with mild-to-moderate Alzheimer’s disease. Participants received 30 g daily of an MCT oil containing primarily C8 and C10 fatty acids (n=11) or a predominantly C8 formulation (n=6), each for one month. Both formulations approximately doubled brain ketone consumption without changing brain glucose utilization. The relationship between blood ketone concentrations and brain ketone uptake was similar to that observed in healthy young adults. These findings demonstrate that the Alzheimer’s brain retains the capacity to use additional ketones as fuel, helping compensate for impaired glucose metabolism.
A Ketogenic Drink Improves Brain Energy and Some Measures of Cognition in Mild Cognitive Impairment
Fortier M, Castellano CA, Croteau E, and colleagues
Alzheimer’s & Dementia, 2019; 15(5):625-634
In this randomized, placebo-controlled study, 52 people with mild cognitive impairment were assigned to receive 30 g daily of ketogenic MCTs or a matching placebo for six months. PET imaging demonstrated approximately doubled brain ketone metabolism with MCT supplementation, improving total brain energy availability without increasing glucose utilization. Improvements in selected measures of memory, language, executive function, and processing speed were observed relative to baseline, and several cognitive improvements were positively associated with increased brain ketone uptake. These findings suggest that MCT supplementation can partially compensate for impaired brain glucose metabolism in mild cognitive impairment.
The Effect of Simultaneous Application of Plant-Rich Ketogenic Diet and Intermittent Fasting on Early-to-Mid-Stage Alzheimer’s Disease: A Randomised Controlled Trial
Tağraf B, Kaygusuz D, Yerlikaya D, Oğul ÖE, Hanoğlu L
Journal of Nutrition, Health & Aging, 2026; 30(9):100930.
This randomized clinical trial investigated a plant-rich ketogenic diet combined with intermittent fasting in 60 participants with early-to-mid-stage Alzheimer’s disease. After six months, mean Mini-Mental State Examination (MMSE) scores increased by 0.9 points in the intervention group and declined by 1.5 points in controls, with a significant difference in cognitive change between groups. The findings suggest that this combined dietary approach may help stabilize cognitive performance in some individuals with Alzheimer’s disease. Because the intervention included both dietary carbohydrate restriction and intermittent fasting, the independent contribution of each component cannot be determined. Larger studies are needed to confirm the findings and assess long-term outcomes.
Parkinson’s Disease & Other Neurological Disorders
Clinical studies and scientific research investigating ketogenic diets, ketone supplements, and alternative brain fuels in Parkinson’s disease and other neurological conditions.
Future Research Directions
Small clinical studies of ketogenic interventions in Parkinson’s disease have reported improvements in various motor and nonmotor symptoms, although findings have differed among studies and evidence of cognitive benefits remains limited. These observations raise important questions about which patients may benefit, which symptoms are most responsive, and which dietary approaches are most effective.
An important direction for future research would be to compare coconut oil, C8/C10 MCT oil, and combinations of the two. Their different fatty acid compositions could produce differences in ketone availability, metabolism, tolerability, and potentially clinical responses. Controlled studies measuring blood ketones alongside motor symptoms, nonmotor symptoms, and cognitive function could help determine whether one formulation or combination offers advantages over another.
Treatment of Parkinson Disease with Diet-Induced Hyperketonemia: A Feasibility Study
VanItallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB
Neurology, 2005; 64(4):728-730
This early pilot study investigated the feasibility of a ketogenic diet in people with Parkinson’s disease. Five of seven enrolled participants successfully followed a ketogenic diet at home for 28 days. All five showed improvements in Unified Parkinson’s Disease Rating Scale (UPDRS) scores during the intervention. The researchers proposed that ketones might help compensate for impaired mitochondrial complex I activity implicated in Parkinson’s disease. Although encouraging, the findings were preliminary because the study was small and lacked a control group. Other factors, including weight loss and placebo effects, could have contributed to the improvements.
Low-Fat Versus Ketogenic Diet in Parkinson’s Disease: A Pilot Randomized Controlled Trial
Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP
Movement Disorders, 2018; 33(8):1306-1314
In this eight-week randomized controlled trial, 47 people with Parkinson’s disease were assigned to either a ketogenic diet or a low-fat diet, with 38 completing the study. Both groups experienced significant improvements in motor and nonmotor symptoms. However, the ketogenic group showed significantly greater improvement in nonmotor symptoms (41% versus 11%), particularly urinary problems, pain, fatigue, daytime sleepiness, and cognitive complaints. There were no significant differences between groups in improvements in motor symptoms. These preliminary findings suggest that ketogenic diets may offer benefits for certain nonmotor symptoms of Parkinson’s disease, although larger, longer-duration studies are needed.
A Mixed Methods Feasibility Study of a Ketogenic Diet as Treatment for Parkinson’s Disease
Worster K, Colgan D, Vita A, and colleagues
Frontiers in Nutrition, 2025; 12:1601446
This 12-week pilot study evaluated a modified, low-dairy ketogenic diet in 12 people with Parkinson’s disease. All participants completed the intervention and achieved nutritional ketosis. The diet emphasized limiting dairy products while incorporating plant-based foods and adequate micronutrients. Improvements were observed in total Parkinson’s disease rating scale scores, balance, freezing of gait, and quality of life. Participants also experienced weight loss, and most reported no worsening of constipation. These findings suggest that a low-dairy ketogenic diet is feasible for people with Parkinson’s disease, although larger randomized controlled trials are needed to determine its effectiveness.
A Randomized Safety and Feasibility Crossover Trial of Two Mediterranean-Ketogenic Interventions in Individuals with Parkinson’s Disease
Tosefsky K, Lam JST, Wang YN, and colleagues
Journal of Parkinson’s Disease, 2026; 16(2):332-350
This randomized crossover trial compared two dietary approaches in people with Parkinson’s disease: a carbohydrate-restricted Mediterranean ketogenic diet and a Mediterranean diet supplemented with MCT oil. Participants followed each intervention for eight weeks, separated by an eight-week washout period. Of 52 randomized participants, 48 began the study and 33 completed both interventions. The ketogenic diet produced higher blood ketone concentrations, while the MCT-supplemented Mediterranean diet was associated with modest improvements in patient-reported motor activities of daily living and motor complications. However, there were no significant differences in clinical outcomes between the two diets. Neither intervention significantly changed blood lipid levels. These preliminary findings support further research into ketogenic dietary strategies for Parkinson’s disease.
Epilepsy, Seizures, and Ketogenic Therapies
Research exploring the effects of ketogenic diets, exogenous ketones, and metabolic therapies on seizure activity and neuronal excitability. These publications include scientific reviews and experimental studies investigating mechanisms beyond ATP production, including adenosine signaling, neurotransmitter balance, and mitochondrial function.
Ketone Administration for Seizure Disorders: History and Rationale for Ketone Esters and Metabolic Alternatives
Poff AM, Rho JM, D’Agostino DP
Frontiers in Neuroscience, 2019; 13:1041. Review.
This comprehensive review examines the scientific rationale for using ketone bodies and exogenous ketone supplements to help control seizures. The authors discuss potential anticonvulsant mechanisms involving adenosine receptors, ATP-sensitive potassium channels, mitochondrial function, oxidative stress, GABA synthesis, glutamatergic signaling, inflammation, and epigenetic regulation. They also review the development of ketone esters and other formulations that can raise circulating ketones without requiring strict carbohydrate restriction. Although ketogenic diets are established treatments for certain forms of drug-resistant epilepsy, the independent therapeutic effects of exogenous ketone supplements require further clinical investigation.
Adenosine A1 Receptor Antagonism Abolished the Anti-seizure Effects of Exogenous Ketone Supplementation in Wistar Albino Glaxo Rijswijk Rats
Kovács Z, D’Agostino DP, Dobolyi A, Ari C
Frontiers in Molecular Neuroscience, 2017; 10:235
This experimental study investigated the effects of exogenous ketone supplementation on absence seizure activity in WAG/Rij rats. Seven days of supplementation with either a ketone ester or a combination of beta-hydroxybutyrate mineral salts and MCT oil increased blood ketone levels and significantly reduced EEG spike-wave discharges. Administration of an adenosine A1 receptor antagonist abolished the antiseizure effect of the ketone salt/MCT combination. These findings suggest that adenosine A1 receptor signaling contributes to the anticonvulsant effects of exogenous ketones, providing evidence of a mechanism beyond their role in energy production. Further studies are needed to establish clinical relevance in human epilepsy.
Putative Role of Adenosine A1 Receptors in Exogenous Ketone Supplements-Evoked Anti-Epileptic Effect
Kovács Z, Rauch E, D’Agostino DP, Ari C
International Journal of Molecular Sciences, 2024; 25(18):9869. Review.
This scientific review examines the potential role of adenosine A1 receptors in the antiseizure effects of exogenous ketone supplements. The authors discuss evidence that therapeutic ketosis may increase brain adenosine levels and enhance A1 receptor activity, potentially reducing neuronal excitability through effects on glutamatergic signaling and potassium channels, including ATP-sensitive potassium channels. The review also considers experimental studies of ketone esters, ketone salts, and combinations with MCT oil. The proposed adenosine-mediated mechanism suggests that ketone supplements may have neurological effects beyond providing an alternative source of energy. Additional clinical research is needed to establish the efficacy and safety of exogenous ketone supplements for epilepsy.
Brain Energy & Metabolism
Research on brain glucose hypometabolism, ketone uptake and utilization, mitochondrial energy production, and the potential of alternative fuels to support brain metabolism during aging and neurological disorders.
These studies help explain the scientific rationale for ketogenic interventions. They examine how ketones contribute to brain energy availability and whether alternative fuels can help compensate for impaired glucose metabolism.
Brain Glucose and Acetoacetate Metabolism: A Comparison of Young and Older Adults
Nugent S, Tremblay S, Chen KW, and colleagues
Neurobiology of Aging, 2014; 35(6):1386-1395
This dual-tracer PET imaging study compared brain glucose and acetoacetate metabolism in 20 healthy younger adults and 24 healthy older adults. Global gray matter glucose metabolism was approximately 8% lower in the older group, with reductions in several brain regions. In contrast, the difference in global gray matter acetoacetate metabolism was not statistically significant, although some regional measures of ketone uptake differed with age. These findings suggest that age-related changes in brain glucose and ketone metabolism are not necessarily equivalent and support further investigation of ketones as an alternative brain energy source.
Inverse Relationship Between Brain Glucose and Ketone Metabolism in Adults During Short-Term Moderate Dietary Ketosis: A Dual Tracer Quantitative Positron Emission Tomography Study
Courchesne-Loyer A, Croteau E, Castellano CA, and colleagues
Journal of Cerebral Blood Flow & Metabolism, 2017; 37(7):2485-2493
This dual-tracer PET imaging study investigated brain glucose and ketone metabolism in healthy adults during short-term moderate dietary ketosis. As circulating ketone concentrations increased, brain ketone uptake increased while glucose utilization decreased. The findings demonstrate that the healthy human brain can adjust its use of energy substrates according to ketone availability, supporting the potential of ketones to provide an alternative source of energy when glucose utilization is impaired. This metabolic adaptation does not, by itself, establish clinical benefits in neurological disorders.
Brain Energy Rescue: An Emerging Therapeutic Concept for Neurodegenerative Disorders of Ageing
Cunnane SC, Trushina E, Morland C, and colleagues
Nature Reviews Drug Discovery, 2020; 19(9):609-633
This comprehensive review examines impaired brain energy metabolism in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis. The authors discuss how reduced glucose utilization, mitochondrial dysfunction, and other metabolic disturbances may contribute to neurodegeneration. Potential strategies for restoring brain energy availability include ketogenic interventions, alternative fuels such as lactate, improvements in insulin sensitivity and mitochondrial function, and complementary lifestyle approaches. The review presents brain energy rescue as a promising therapeutic concept while emphasizing the need for further clinical investigation.
The Effects of Acute Ketone Monoester Supplementation on Brain Insulin Responsiveness and Cognitive Performance: Results of a Randomized, Double-Blind, Placebo-Controlled Crossover Trial in Older Men with Overweight
Nijssen KMR, Adam TC, Mensink RP, Joris PJ
Metabolism, 2026; 182:156672.
This randomized, double-blind crossover trial examined the acute effects of a ketone monoester on brain insulin responsiveness and cognition in 18 older men with overweight. Supplementation increased blood beta-hydroxybutyrate to approximately 2.9 mmol/L and altered cerebral blood-flow responses to intranasal insulin in several brain regions. Attention and psychomotor speed improved modestly compared with placebo, while memory and executive function did not significantly change. Resting cerebral blood flow also decreased. These findings suggest that acute ketosis influences brain insulin-related physiology, although the clinical significance and effects of sustained supplementation remain uncertain.
Effects of Oral Ketone Ester on Brain Metabolism and Cognition: A Randomized Controlled Trial
Manolopoulos A, Avgerinos K, Chen Q, Egan JM, Kapogiannis D
Alzheimer’s & Dementia, 2025; 21(Suppl 5):e097825. Podium Presentation Abstract.
This randomized, double-blind, placebo-controlled trial enrolled 50 cognitively intact adults over age 55 with metabolic syndrome, a risk factor for Alzheimer’s disease. Participants received 25 g of oral ketone ester or an isocaloric placebo three times daily for four weeks. Magnetic resonance spectroscopy demonstrated significantly increased brain beta-hydroxybutyrate concentrations and reduced brain glutamate concentrations following ketone ester administration. Cognitive testing showed improvements in some memory measures in both groups, with nonsignificant trends favoring ketone ester. Improvements in delayed verbal recall and digit-symbol substitution were observed within the ketone ester group. The findings provide preliminary evidence that oral ketone esters can increase brain ketone availability and alter brain metabolism, while larger trials are needed to establish cognitive benefits.
Insulin, Ketone Bodies, and Mitochondrial Energy Transduction
Sato K, Kashiwaya Y, Keon CA, and colleagues
FASEB Journal, 1995; 9(8):651-658
This foundational laboratory study examined the effects of ketone bodies and insulin on mitochondrial energy metabolism in isolated working rat hearts. Adding a physiological ratio of beta-hydroxybutyrate and acetoacetate increased cardiac work relative to oxygen consumption by approximately 25%, while the combination of ketones and insulin increased efficiency by approximately 36%. Ketone administration also increased acetyl-CoA concentrations and altered several metabolites of the citric acid cycle. Although these findings were obtained in cardiac tissue, they provided important evidence that ketones can influence mitochondrial energy metabolism beyond simply serving as an alternative fuel.
Beta-Hydroxybutyrate: A Signaling Metabolite
Newman JC, Verdin E
Annual Review of Nutrition, 2017; 37:51-76. Review.
This comprehensive review examines the biological functions of beta-hydroxybutyrate (BHB) beyond its role as an alternative energy substrate. The authors describe how BHB can influence cellular signaling through cell-surface receptors, histone deacetylase inhibition, protein beta-hydroxybutyrylation, and other mechanisms involved in gene regulation, inflammation, and cellular metabolism. The review also discusses differences between the naturally produced D/R-BHB and the L/S-BHB enantiomer, including their metabolism and potential signaling activities. These findings suggest that ketone bodies may influence brain function and aging through mechanisms that are partly independent of ATP production.
Interplay Between Age, APOE ε4 and the Metabolome in Plasma and Brain in Alzheimer’s Disease
Amin N, Liu J, Sproviero W, and colleagues
Translational Psychiatry, 2025; 15:460.
This large-scale investigation integrated plasma metabolomic and proteomic data with brain tissue analyses to examine relationships among aging, APOE ε4, and Alzheimer’s disease. APOE ε4 carriers exhibited higher circulating beta-hydroxybutyrate (BHB) concentrations beginning as early as 37 years of age, while altered BHB and branched-chain amino acid metabolism was also associated with Alzheimer’s disease. The authors identified changes in metabolic and cellular pathways, including mitochondrial energy metabolism. Their findings suggest that elevated plasma BHB may reflect an early metabolic response to processes associated with Alzheimer’s disease rather than increased ketone availability within the brain. The study did not establish the source of the elevated circulating BHB or determine whether these metabolic changes are protective, compensatory, or detrimental.
Animal & Laboratory Research
Experimental studies investigating the effects of ketones, ketogenic diets, and medium-chain triglycerides on neuronal survival, mitochondrial function, inflammation, oxidative stress, and other mechanisms involved in neurodegenerative disorders.
These studies provide insights into potential biological mechanisms but do not necessarily predict clinical benefits in humans.
D-Beta-Hydroxybutyrate Protects Neurons in Models of Alzheimer’s and Parkinson’s Disease
Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL
Proceedings of the National Academy of Sciences USA, 2000; 97(10):5440-5444
This landmark laboratory study investigated the neuroprotective effects of D-beta-hydroxybutyrate (BHB) in experimental models relevant to Alzheimer’s and Parkinson’s diseases. In cultured hippocampal neurons exposed to amyloid-beta, 4 mM BHB increased neuronal survival and preserved neurite growth. BHB also protected dopaminergic neurons against MPP+, a mitochondrial complex I inhibitor used to model Parkinson’s disease. These findings provided early evidence that ketones may protect neurons against certain metabolic and neurotoxic insults, supporting further investigation of ketogenic interventions in neurodegenerative disorders.
D-Beta-Hydroxybutyrate Rescues Mitochondrial Respiration and Mitigates Features of Parkinson Disease
Tieu K, Perier C, Caspersen C, and colleagues
Journal of Clinical Investigation, 2003; 112(6):892-901
This experimental study investigated the neuroprotective effects of D-beta-hydroxybutyrate (D-BHB) in mice treated with MPTP, a neurotoxin that inhibits mitochondrial complex I and produces Parkinson-like neurodegeneration. Administration of D-BHB partially protected dopaminergic neurons in the substantia nigra and reduced motor deficits. The protective effects were associated with improved mitochondrial respiration and ATP production through a mechanism dependent on mitochondrial complex II. These findings suggest that ketones may help compensate for certain defects in mitochondrial energy metabolism and protect vulnerable neurons. Although promising, these results were obtained in an animal model and do not establish clinical benefits in people with Parkinson’s disease.
A Ketone Ester Diet Exhibits Anxiolytic and Cognition-Sparing Properties, and Lessens Amyloid and Tau Pathologies in a Mouse Model of Alzheimer’s Disease
Kashiwaya Y, Bergman C, Lee JH, and colleagues
Neurobiology of Aging, 2013; 34(6):1530-1539
This long-term study examined the effects of a ketone ester diet in the 3xTgAD mouse model of Alzheimer’s disease, which develops amyloid-beta and tau pathology. Thirty male mice were assigned to either a diet containing a ketone ester composed of D-beta-hydroxybutyrate and (R)-1,3-butanediol or an isocaloric carbohydrate-based diet, beginning at 8.5 months of age. Over the following months, ketone ester-fed mice exhibited significantly less anxiety and modest improvements in learning and memory. Brain tissue analysis also revealed reduced amyloid-beta accumulation and hyperphosphorylated tau pathology in several regions, including the hippocampus and amygdala. These findings provided early evidence that sustained ketone ester supplementation may influence both behavior and neuropathology in an experimental model of Alzheimer’s disease.
Effects of a Dietary Ketone Ester on Hippocampal Glycolytic and Tricarboxylic Acid Cycle Intermediates and Amino Acids in a 3xTgAD Mouse Model of Alzheimer’s Disease
Pawlosky RJ, Kemper MF, Kashiwaya Y, King MT, Mattson MP, Veech RL
Journal of Neurochemistry, 2017; 141(2):195-207
This study examined brain metabolism in the 3xTgAD mouse model of Alzheimer’s disease after eight months of dietary supplementation with a ketone ester composed of D-beta-hydroxybutyrate and (R)-1,3-butanediol. Compared with controls, ketone ester-fed mice had higher hippocampal concentrations of TCA cycle intermediates, glycolytic intermediates, and N-acetylaspartate (NAA), a metabolite associated with neuronal energy metabolism and myelin maintenance. Mitochondrial redox status was more reduced, the energy available from ATP hydrolysis was greater, and markers of protein and lipid oxidation were lower. These findings suggest that sustained ketone availability may help restore aspects of impaired brain energy metabolism and reduce oxidative stress in this experimental Alzheimer’s model.
A Dietary Ketone Ester Normalizes Abnormal Behavior in a Mouse Model of Alzheimer’s Disease
Pawlosky RJ, Kashiwaya Y, King MT, Veech RL
International Journal of Molecular Sciences, 2020; 21(3):1044
This experimental study investigated the effects of long-term dietary ketone ester supplementation on behavioral abnormalities in the 3xTgAD mouse model of Alzheimer’s disease. The investigators examined changes in activity and behavior associated with disease progression and reported that ketone ester supplementation reduced several abnormal behavioral responses. These findings complement earlier studies demonstrating effects of ketone esters on brain energy metabolism, amyloid and tau pathology, and learning and memory in this mouse model. Further studies are needed to determine whether similar benefits occur in people with Alzheimer’s disease.
Effect of Dietary Ketosis and Nicotinamide Riboside on Hippocampal Krebs Cycle Intermediates and Mitochondrial Energetics in a DNA Repair-Deficient 3xTg/POLβ+/- Alzheimer Disease Mouse Model
Pawlosky RJ, Demarest TG, King MT, Estrada D, Veech RL, Bohr VA
Journal of Neurochemistry, 2025; 169(1):e16295
This study investigated the effects of dietary ketosis, nicotinamide riboside (NR), and their combination on hippocampal metabolism in older male and female mice, including a transgenic Alzheimer’s disease model with impaired DNA repair. Following 12 weeks of treatment, researchers measured Krebs cycle intermediates, mitochondrial redox status, and the free energy of the mitochondrial Complex I-II system. Both ketosis and NR influenced mitochondrial energetics, but responses differed by sex. In male Alzheimer’s-model mice, NR supplementation and dietary ketosis helped restore mitochondrial energy measures, whereas in females, ketosis alone restored the measured energy profile. These findings highlight potential metabolic benefits of ketosis and NAD+ precursor supplementation, as well as the importance of sex-specific responses.
Exogenous Ketone Supplements Improved Motor Performance in Preclinical Rodent Models
Ari C, Murdun C, Goldhagen C, and colleagues
Nutrients, 2020; 12(8):2459
This experimental study investigated the effects of ketone esters, ketone salts, MCT oil combinations, and a ketogenic diet on motor performance in several rodent models, including rats and mice with GLUT1 deficiency syndrome. Motor performance was assessed using an accelerating rotarod test. Several ketogenic supplement formulations improved motor performance, including combinations of ketone ester and MCT oil. Responses varied according to the animal model, formulation, and duration of supplementation. These findings suggest that exogenous ketones and combinations with MCTs may influence physical and neurological function, supporting further investigation in human neurological disorders.
Exogenous Ketone Supplements Reduce Anxiety-Related Behavior in Sprague-Dawley and Wistar Albino Glaxo/Rijswijk Rats
Ari C, Kovacs Z, Juhasz G, and colleagues
Frontiers in Molecular Neuroscience, 2016; 9:137
This preclinical study examined the effects of exogenous ketone supplements on anxiety-related behavior in two rat strains. Investigators evaluated ketone esters, beta-hydroxybutyrate mineral salts, and combinations of ketone salts with MCT oil, using both short-term and longer-term supplementation. Several formulations reduced anxiety-related behaviors in the elevated plus maze test, although responses differed among treatments and animal models. The results suggest that ketogenic supplements may influence behavioral function through mechanisms beyond their role as alternative energy substrates. Further research is needed to determine whether similar effects occur in humans.
Ketones, Protein Homeostasis, and Alzheimer’s Pathology
Emerging laboratory and animal research suggests that beta-hydroxybutyrate (BHB) may influence the folding, aggregation, and clearance of proteins implicated in Alzheimer’s disease, including amyloid-beta and tau. These studies investigate potential effects on protein homeostasis (proteostasis) that extend beyond the use of ketones as an alternative energy source. Findings remain preclinical, and their relevance to human treatment requires further investigation.
Beta-Hydroxybutyrate Is a Metabolic Regulator of Proteostasis in the Aged and Alzheimer Disease Brain
Madhavan SS, Roa Diaz S, Peralta S, and colleagues
Cell Chemical Biology, 2025; 32(1):174-191.e8.
This laboratory and animal study identified a potential role for beta-hydroxybutyrate (BHB) in regulating the solubility and clearance of misfolded proteins associated with aging and Alzheimer’s disease. BHB selectively increased the insolubility of certain structurally abnormal proteins, including amyloid-beta, through a mechanism that did not require changes in pH or covalent protein modification. The investigators demonstrated effects in cultured cells, nematode models of amyloid-beta toxicity, and aged mouse brain following ketone ester administration. These findings suggest that BHB may help regulate proteostasis and facilitate clearance of pathological proteins through mechanisms beyond its use as an energy substrate. Clinical significance remains to be established.
Ketone Body Beta-Hydroxybutyrate Restores Neuronal Tau Proteostasis via Ketolysis-Independent Mechanism
Rossitto LAM, Foo J, Di Silvestri JM, and colleagues
bioRxiv, February 2, 2026. Preprint; not peer-reviewed.
This preclinical study investigated the effects of beta-hydroxybutyrate (BHB) on tau protein homeostasis in experimental models of Alzheimer’s disease and related tauopathies. A ketone ester diet reduced pathological tau accumulation and neuroinflammatory markers in a transgenic mouse model. Additional experiments using cellular, biochemical, and animal models showed that BHB enhanced neuronal tau proteostasis and reduced tau aggregation and secretion. Importantly, a ketolysis-resistant BHB enantiomer reproduced key effects, suggesting that these actions can occur independently of BHB oxidation for ATP production. These preliminary findings identify a potential mechanism linking ketosis to regulation of pathological tau, but require peer review, independent replication, and clinical investigation.
Foundational Ketone Research
Landmark studies that established our understanding of ketone production, transport, and utilization, particularly the brain’s ability to use ketones as an alternative energy source during fasting and carbohydrate restriction.
This pioneering research laid the biochemical foundation for modern investigations of ketogenic diets, MCT oils, ketone supplements, and their potential applications in neurological and metabolic disorders.
Brain Metabolism During Fasting
Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr
Journal of Clinical Investigation, 1967; 46(10):1589-1595
This landmark human study measured brain fuel utilization in three individuals after five to six weeks of prolonged fasting. Using cerebral blood flow measurements and differences in blood substrate concentrations entering and leaving the brain, the researchers demonstrated that beta-hydroxybutyrate and acetoacetate had replaced glucose as the predominant fuels consumed by the brain. These findings established that the human brain can adapt to prolonged fasting by obtaining much of its energy from ketones, reducing its dependence on glucose and the need to break down body protein for glucose production. This discovery provided a fundamental scientific basis for later investigations of ketogenic interventions in neurological disorders.
Fuel Metabolism in Starvation
Cahill GF Jr
Annual Review of Nutrition, 2006; 26:1-22
In this landmark review, Dr. George Cahill summarizes decades of research on human fuel metabolism during prolonged fasting. He explains how declining insulin levels promote fatty acid mobilization, hepatic ketone production, and the gradual adaptation of the brain to using beta-hydroxybutyrate and acetoacetate for energy. This metabolic adaptation reduces the brain’s requirement for glucose and helps preserve body protein during prolonged starvation. Cahill also discusses the potential advantages of ketones for cellular energy production and their possible therapeutic applications in conditions involving impaired energy metabolism. The review provides an important foundation for understanding the modern use of ketogenic diets and ketone supplements.
The Therapeutic Implications of Ketone Bodies: The Effects of Ketone Bodies in Pathological Conditions: Ketosis, Ketogenic Diet, Redox States, Insulin Resistance, and Mitochondrial Metabolism
Veech RL
Prostaglandins, Leukotrienes and Essential Fatty Acids, 2004; 70(3):309-319
In this influential review, Dr. Richard Veech examines the biochemical basis for the potential therapeutic effects of ketone bodies. He discusses how ketone metabolism influences mitochondrial energy production, ATP hydrolysis, cellular redox states, and oxidative stress. The review proposes that mild ketosis may offer benefits in conditions involving impaired fuel availability, insulin resistance, oxidative injury, and hypoxia. Veech also discusses the potential advantages of administering ketone bodies or ketone esters directly, anticipating later research on exogenous ketone supplements. This paper helped establish the scientific rationale for investigating ketones as therapeutic agents in neurological and metabolic disorders.
Ketone Bodies, Potential Therapeutic Uses
Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr
IUBMB Life, 2001; 51(4):241-247
This influential paper reviews the importance of ketone bodies as alternative fuels for the brain during prolonged fasting and explores their potential therapeutic applications. The authors discuss evidence that beta-hydroxybutyrate may improve mitochondrial energy efficiency, increase the energy available from ATP hydrolysis, and protect neurons against certain forms of metabolic and neurotoxic injury. They propose that these properties could be valuable in neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and drug-resistant epilepsy. The paper also anticipates the development of orally administered ketone esters and other synthetic ketone formulations as practical alternatives to prolonged fasting or strict ketogenic diets.
Additional Research Topics
Scientific research exploring additional biological effects and potential applications of coconut oil, medium-chain fatty acids, and ketones, including fatty acid metabolism, antimicrobial activity, inflammation, immune responses, and possible connections between infections and neurological disorders.
These publications include clinical studies, laboratory experiments, scientific reviews, and research hypotheses. Findings should be interpreted according to the strength and limitations of the evidence.
Coconut Oil, Lauric Acid, and Medium-Chain Fatty Acid Metabolism
Research examining the fatty acid composition of coconut oil, particularly lauric acid (C12), and its implications for digestion, absorption, energy metabolism, ketone production, cholesterol, and antimicrobial activity.
The Properties of Lauric Acid and Their Significance in Coconut Oil
Dayrit FM
Journal of the American Oil Chemists’ Society, 2015; 92:1-15. Review.
This comprehensive review examines the properties of lauric acid (C12), which accounts for approximately 45-53% of the fatty acids in coconut oil. The author discusses how lauric acid differs from longer-chain saturated fatty acids in digestion, absorption, transport, and metabolism. Evidence reviewed indicates that a substantial proportion of ingested lauric acid can reach the liver through the portal circulation, where it may be oxidized for energy or contribute to ketone production. The review also addresses effects on cholesterol and fat metabolism, along with the antimicrobial properties of lauric acid and monolaurin. These distinctive characteristics provide an important scientific rationale for investigating differences between coconut oil and conventional C8/C10 MCT oil.
MCT Oil and Cognitive Function in Healthy Adults
Clinical research investigating whether MCT supplementation influences specific aspects of cognitive performance in otherwise healthy individuals.
Both a Single Dose and a 4-Week Daily Regimen of Medium-Chain Triglycerides Boost Certain Aspects of Cognitive Function in Young Adults: A Randomized Controlled Trial
Yuuki IW, Dora K, Matsumura T, and colleagues
Physiology & Behavior, 2026; 305:115212.
This randomized controlled trial investigated the effects of medium-chain triglyceride (MCT) oil on cognitive performance in 36 healthy young adults, comparing 12 g of MCT oil with olive oil. Following a single dose, the MCT group demonstrated better inhibitory control than the comparison group. After four weeks of daily supplementation, working memory performance was also better in the MCT group. Benefits were limited to selected cognitive measures, and the results do not establish broader cognitive enhancement or effects in older adults or individuals with Alzheimer’s disease. The findings suggest that MCT supplementation may influence certain aspects of cognitive performance even in young, cognitively healthy individuals.
Virgin Coconut Oil and COVID-19
Two randomized clinical studies conducted in the Philippines investigated virgin coconut oil as an adjunct to usual care for COVID-19, examining inflammatory markers and symptom recovery. These findings are preliminary and do not establish coconut oil as a substitute for established medical treatments.
Virgin Coconut Oil (VCO) Supplementation Relieves Symptoms and Inflammation Among COVID-19 Positive Adults: A Single-Blind Randomized Trial
Angeles-Agdeppa I, Nacis JS, Dayrit FM, Tanda KV
Journal of Nutritional Science, 2024; 13:e5
This 28-day randomized, single-blind clinical trial evaluated virgin coconut oil supplementation as an adjunct to usual care in 76 adults with laboratory-confirmed COVID-19. Participants receiving virgin coconut oil experienced earlier resolution of symptoms and normalization of C-reactive protein (CRP) levels compared with controls. The intervention group was reported to be symptom-free with normalized CRP by day 14, compared with days 23 and 25, respectively, in the control group. These findings suggest possible effects on inflammation and symptom recovery, although additional independent, well-controlled studies are needed to establish clinical effectiveness.
Virgin Coconut Oil Is Effective in Lowering C-Reactive Protein Levels Among Suspect and Probable Cases of COVID-19
Angeles-Agdeppa I, Nacis JS, Capanzana MV, Dayrit FM, Tanda KV
Journal of Functional Foods, 2021; 83:104557
This 28-day randomized, double-blind controlled trial investigated virgin coconut oil supplementation in 63 adults classified as suspected or probable COVID-19 cases. Participants received standardized meals with or without added virgin coconut oil. The coconut oil group experienced a greater decline in C-reactive protein (CRP), an inflammatory marker, with average CRP levels reaching the study’s normal range by day 14. The results suggested a possible anti-inflammatory effect of virgin coconut oil during acute infection, although confirmation in larger clinical studies is necessary.
Viral Hypotheses of Alzheimer’s Disease and Antimicrobial Effects of Fatty Acids
Research has explored whether certain infections, including herpes simplex virus type 1 (HSV-1), may contribute to Alzheimer’s disease in susceptible individuals. Separate laboratory studies have demonstrated antiviral activity of some medium-chain fatty acids and monoglycerides against enveloped viruses.
These findings are scientifically interesting but do not establish that infections cause all cases of Alzheimer’s disease or that consuming coconut oil prevents or treats viral infections. Further clinical research is needed.
Herpes Simplex Virus Type 1 in Alzheimer’s Disease: The Enemy Within
Itzhaki RF, Wozniak MA
Journal of Alzheimer’s Disease, 2008; 13(4):393-405
This review examines evidence supporting the hypothesis that herpes simplex virus type 1 (HSV-1) may contribute to Alzheimer’s disease, particularly in individuals carrying the APOE4 allele. The authors discuss the presence of HSV-1 in brain tissue, possible interactions between viral infection and genetic susceptibility, and mechanisms by which viral activity could contribute to neuronal damage and Alzheimer’s-related pathology. The infectious hypothesis remains an active area of investigation, and the evidence does not establish that HSV-1 is a necessary or sufficient cause of Alzheimer’s disease.
Microbes and Alzheimer’s Disease
Itzhaki RF, Lathe R, Balin BJ, and colleagues
Journal of Alzheimer’s Disease, 2016; 51(4):979-984. Editorial.
In this editorial, an international group of 33 researchers and clinicians called for greater investigation of infectious agents as potential contributors to Alzheimer’s disease. The authors reviewed evidence implicating herpes simplex virus type 1 (HSV-1), Chlamydia pneumoniae, spirochetes, and other microbes in Alzheimer’s pathology. They discussed possible connections between infection, neuroinflammation, amyloid-beta accumulation, and tau abnormalities, including the hypothesis that amyloid-beta may initially function as an antimicrobial defense. The authors advocated further investigation of antimicrobial and antiviral approaches to Alzheimer’s disease. Although the infectious hypothesis remains under investigation, this publication helped bring greater attention to a potentially important area of research.
Inactivation of Enveloped Viruses and Killing of Cells by Fatty Acids and Monoglycerides
Thormar H, Isaacs CE, Brown HR, Barshatzky MR, Pessolano T
Antimicrobial Agents and Chemotherapy, 1987; 31(1):27-31
This laboratory study investigated the effects of free fatty acids and monoglycerides on several enveloped viruses, including herpes simplex virus, vesicular stomatitis virus, and visna virus. Certain medium-chain saturated fatty acids and long-chain unsaturated fatty acids demonstrated antiviral activity by disrupting viral envelopes. Their monoglycerides were sometimes active at lower concentrations than the corresponding free fatty acids. These findings established important mechanisms of lipid-mediated viral inactivation under laboratory conditions but do not demonstrate that dietary coconut oil produces antiviral effects in humans.
Development and Evaluation of Microbicidal Hydrogels Containing Monoglyceride as the Active Ingredient
Kristmundsdottir T, Arnadottir SG, Bergsson G, Thormar H
Journal of Pharmaceutical Sciences, 1999; 88(10):1011-1015
This laboratory study evaluated fatty acids and monoglycerides for antiviral activity against herpes simplex virus type 1 (HSV-1), with the goal of developing topical microbicidal formulations. The researchers investigated monoglyceride-containing hydrogels as a possible approach to reducing exposure to certain infectious pathogens. The findings provided a basis for further development of topical antimicrobial products but did not evaluate oral consumption of coconut oil or demonstrate prevention or treatment of infections in humans.
Download the Scientific Reference List
A comprehensive bibliography of published research on coconut oil, MCT oil, ketones, ketogenic diets, brain aging, Alzheimer’s disease, Parkinson’s disease, and related neurological disorders.
View or Download Reference List (PDF) →
9 pages | Updated December 2025
